Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds virus or component thereof
Reexamination Certificate
2007-06-12
2007-06-12
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds virus or component thereof
C424S130100, C424S134100, C424S141100, C424S147100, C424S211100
Reexamination Certificate
active
09724531
ABSTRACT:
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
REFERENCES:
patent: 4526938 (1985-07-01), Churchill et al.
patent: 4800078 (1989-01-01), Prince et al.
patent: 4880078 (1989-11-01), Inoue et al.
patent: 5128326 (1992-07-01), Balazs et al.
patent: 5290540 (1994-03-01), Prince et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5667988 (1997-09-01), Barbas et al.
patent: 5679377 (1997-10-01), Bernstein et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5762905 (1998-06-01), Burton et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 5824307 (1998-10-01), Johnson
patent: 5840298 (1998-11-01), Brams et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5866125 (1999-02-01), Brams et al.
patent: 5874064 (1999-02-01), Edwards et al.
patent: 5912015 (1999-06-01), Bernstein et al.
patent: 5916597 (1999-06-01), Lee et al.
patent: 5929212 (1999-07-01), Adair et al.
patent: 5934272 (1999-08-01), Lloyd et al.
patent: 5939068 (1999-08-01), Brams et al.
patent: 5955364 (1999-09-01), Brams et al.
patent: 5958765 (1999-09-01), Brams et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 5985320 (1999-11-01), Edwards et al.
patent: 5989463 (1999-11-01), Tracy et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6117980 (2000-09-01), Gonzalez et al.
patent: 6413771 (2002-07-01), Brams et al.
patent: 6537809 (2003-03-01), Brams
patent: 6565888 (2003-05-01), Tracy et al.
patent: 6656467 (2003-12-01), Young et al.
patent: 6685942 (2004-02-01), Brams et al.
patent: 6818216 (2004-11-01), Young et al.
patent: 6855493 (2005-02-01), Young et al.
patent: 2002/0001798 (2002-01-01), Brams et al.
patent: 2004/0005323 (2004-01-01), Brams et al.
patent: 2004/0005324 (2004-01-01), Pilkington et al.
patent: 2004/0076631 (2004-04-01), Brams et al.
patent: 2004/0131609 (2004-07-01), Young et al.
patent: 2005/0002926 (2005-01-01), Young et al.
patent: 2005/0147616 (2005-07-01), Young et al.
patent: WO 91/05548 (1991-05-01), None
patent: WO 92/19244 (1992-11-01), None
patent: WO 94/06448 (1994-03-01), None
patent: WO 96/05229 (1996-02-01), None
patent: 0 699 756 (1996-06-01), None
patent: WO 96/20698 (1996-07-01), None
patent: WO 96/40252 (1996-12-01), None
patent: WO 97/32572 (1997-09-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44013 (1997-11-01), None
patent: WO 98/31346 (1998-07-01), None
patent: WO 98/33919 (1998-08-01), None
patent: WO 99/15154 (1999-04-01), None
patent: WO 99/20253 (1999-04-01), None
patent: WO 99/28471 (1999-06-01), None
patent: WO 99/66903 (1999-12-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/56771 (2000-09-01), None
patent: WO 00/73346 (2000-12-01), None
patent: WO 01/55217 (2001-08-01), None
patent: WO 01/64751 (2001-09-01), None
patent: WO 2006/034292 (2006-03-01), None
Saez-Llorens et al., 1998, “Safety and Pharmacokinetics of an Intramuscular Humanized Monoclonal Antibody to Respiratory Synctial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia”, Pediatric Infect Dis J. 17:787091.
Subramanian et al., “Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Synctial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia”, Pediatric Infect Dis J. 17:110-115 (1998).
Anderson et al., 1985, “Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay,” J. Clin. Microbiol. 22:1050-1052.
Boulianne et al., 1984, “Production of functional chimaeric mouse/human antibody,” Nature 312(5995):643-646.
Carson et al., 1986, “Human lymphocyte hybridomas and monoclonal antibodies,” Adv. Immunol. 38:275-311.
Conrad et al., 1987, “Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic,” Pediatr. Infect. Dis. J. 6(2):152-158.
Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19.
Dorland's Illustrated Medical Dictionary, 1994, 28thed., Philadelphia: WB Saunders p. 874.
Duenas et al., 1996, “In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display,” Immunology 89:1-7.
Duenas et al., 1996, “Selection of phage displayed antibodies based on kinetic constants,” Molecular Immunol. 33(3):279-285.
Everitt et al., 1996, “The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers,” J. Infect. Dis. 174:463-469.
Foote et al., 1995, “Kinetic and affinity limits on antibodies produced during immune response,” Proc. Nat'l Acad. Science USA 92:1254-1256.
Foote et al., 1991, “Kinetic maturation of an immune response,” Nature 352:530-532.
Glaser et al., 1992, “Antibody engineering by codon-based mutagenesis in a filamentous phage vector system,” J. Immunol. 149:3903-3913.
Greenspan et al., 1999, “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology 17:936-937.
Groves et al., 1987, “Production of an ovine monoclonal antibody to testosterone by an interspecies fusion,” Hybridoma 6(1):71-76.
Hall et al., 1985, “Ribavarin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease,” JAMA 254(21):3047-3051.
Hall et al., 1983, “Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study,” N. Engl. J. Med. 308(24):1443-1447.
Hall et al., 1975, “Nosocomial respiratory syncytial virus infections,” N. Engl. J. Med. 293(26):1343-1346.
Haynes et al., 2002, “Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection,” J. Virol. 76(14):6873-6881.
Johnson et al., 1999, “A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19,” J. Infect. Dis. 180(1):35-40.
Karlsson et al., 1997, “Experimental design for kinetic analysis of protein—protein interactions with surface plasmon resonance biosensors,” J Immunol. Meth. 200:121-133.
Knappik et al., 2000, “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,” J. Mol. Biol. 296:57-86.
Liu et al., 1987, “Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells,” Gene 54(1):33-40.
LoBuglio et al., 1989, “Mouse/human chimeric monoclonal antibody in man: kinetics and immune response,” Proc. Natl. Acad. Sci. USA 86(11):4220-4224.
Morrison e
Huse William D.
Johnson Leslie S.
Koenig Scott
Watkins Jeffrey D.
Wu Herren
Chen Stacy B.
Jones Day
MedImmune, Inc.
LandOfFree
Methods of administering/dosing anti-RSV antibodies for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering/dosing anti-RSV antibodies for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering/dosing anti-RSV antibodies for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807779